Welcome to LookChem.com Sign In|Join Free
  • or
TRANS-2-PHENYLCYCLOPROPYLAMINE HYDROCHLORIDE, also known as TCP, is a cell-permeable phenylcyclopropylamine that acts as an inhibitor for monoamine oxidase and histone demethylase activities. It is a white to light beige powder or chunks and is known for its ability to form covalent adducts with the enzyme-bound FAD, affecting the function of four members of the flavin-dependent amine oxidase family enzymes.

1986-47-6

Post Buying Request

1986-47-6 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1986-47-6 Usage

Uses

Used in Pharmaceutical Industry:
TRANS-2-PHENYLCYCLOPROPYLAMINE HYDROCHLORIDE is used as an antidepressant for treating depressions that do not respond to other drugs. It is particularly effective due to its action as a non-selective MAO-A/B inhibitor, which helps in modulating the levels of monoamines in the brain, thereby alleviating depressive symptoms.
Used in Enzyme Inhibition:
TRANS-2-PHENYLCYCLOPROPYLAMINE HYDROCHLORIDE is used as an enzyme inhibitor for inhibiting the activities of MAO A/B and LSD1/2. It forms a covalent adduct with the enzyme-bound FAD, thereby preventing the demethylation activities of LSD1-CoREST and LSD1-HCF-1 complexes. This inhibition is essential for controlling the replication and latent infection of α-herpesviruses such as HSV and VZV.
Used in Stem Cell Research:
TRANS-2-PHENYLCYCLOPROPYLAMINE HYDROCHLORIDE is used as a reprogramming agent in the field of stem cell research. When combined with other compounds like CHIR99061, it enables the reprogramming of primary HNEKs (Human Neonatal Epidermal Keratinocytes) into iPS (induced Pluripotent Stem) cells, although with a lower efficiency compared to the use of 4-TFs (Oct4, Klf4, Sox2, and c-Myc).

Biological Activity

Irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO) (K i values are 242, 102 and 16 μ M for LSD1, MAO-A and MAO-B respectively). Inhibits histone demethylation.

Clinical Use

MAOI antidepressant

Synthesis

Tranylcypromine, (±)-trans-2-phenylcyclopropylamine (7.2.10), differs from the drugs described above in that it is not a derivative of hydrazine. It is synthesized from the ethyl ester of 2-phenylcyclopropan carboxylic acid (7.2.7), which is synthesized by the reaction of styrene with ethyl diazoacetate. 2-phenylcyclopropancarboxylic acid ethyl ester (7.2.7) is hydrolyzed by alkali to 2-phenylcyclopropancarboxylic acid (7.2.8) and the trans-isomer is separated for further reactions. The reaction of the trans-isomer with thionyl chloride gives trans-2-phenylcyclopropancarboxylic acid chloride (7.2.9), which upon reaction with sodium azide gives the respective acid azide, which undergoes Curtius rearrangement to the transcyclopropylamine (7.2.10) [48,49].

Drug interactions

Potentially hazardous interactions with other drugs Alcohol: some alcoholic and dealcoholised drinks contain tyramine which can cause hypertensive crisis. Alpha-blockers: enhanced hypotensive effect; avoid with indoramin. Analgesics: CNS excitation or depression with pethidine, other opioids and nefopam - avoid; increased risk of serotonergic effects and convulsions with tramadol - avoid. Antibacterials: increased risk of hypertension and CNS excitation with linezolid and tedizolid - avoid for at least 2 weeks after stopping MAOIs. Antidepressants: enhancement of CNS effects and toxicity. Care with all antidepressants including drug free periods when changing therapies. Antidiabetics: possibly enhanced hypoglycaemic effect. Antiepileptics: antagonism of anticonvulsant effect; avoid carbamazepine with or within 2 weeks of MAOIs. Antihypertensives: enhanced hypotensive effect. Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol. Antipsychotics: effects enhanced by clozapine. Anxiolytics: avoid buspirone with or within 2 weeks of MAOIs. Atomoxetine: avoid concomitant use and for 2 weeks after use; increased risk of convulsions. Bupropion: avoid with or for 2 weeks after MAOIs. Dapoxetine: risk of hypertensive crisis - avoid. Diuretics: enhanced hypotensive effect; avoid with indoramin. Dopaminergics: avoid with entacapone, safinamide and tolcapone; hypertensive crisis with levodopa and rasagiline - avoid for at least 2 weeks after stopping MAOI; hypotension with selegiline. 5HT1 agonist: risk of CNS toxicity with sumatriptan, rizatriptan and zolmitriptan - avoid sumatriptan and rizatriptan for 2 weeks after MAOI. Metaraminol: risk of hypertensive crisis - avoid for at least 2 weeks after stopping MAOIs. Methyldopa: avoid concomitant use. Opicapone: avoid concomitant use. Sympathomimetics: hypertensive crisis with sympathomimetics - avoid. Tetrabenazine: risk of CNS excitation and hypertension avoid.

Metabolism

Tranylcypromine undergoes considerable hepatic metabolism, including breakdown of the side chain and probably conjugation. Excretion is renal mainly as metabolites.

Check Digit Verification of cas no

The CAS Registry Mumber 1986-47-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,9,8 and 6 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1986-47:
(6*1)+(5*9)+(4*8)+(3*6)+(2*4)+(1*7)=116
116 % 10 = 6
So 1986-47-6 is a valid CAS Registry Number.
InChI:InChI=1/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/p+1/t8-,9+/m0/s1

1986-47-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (P8511)  trans-2-Phenylcyclopropylaminehydrochloride  

  • 1986-47-6

  • P8511-250MG

  • 458.64CNY

  • Detail
  • Sigma

  • (P8511)  trans-2-Phenylcyclopropylaminehydrochloride  

  • 1986-47-6

  • P8511-1G

  • 1,387.62CNY

  • Detail
  • Sigma

  • (P8511)  trans-2-Phenylcyclopropylaminehydrochloride  

  • 1986-47-6

  • P8511-5G

  • 5,527.08CNY

  • Detail
  • Aldrich

  • (P22370)  trans-2-Phenylcyclopropylaminehydrochloride  97%

  • 1986-47-6

  • P22370-1G

  • 1,751.49CNY

  • Detail
  • Aldrich

  • (P22370)  trans-2-Phenylcyclopropylaminehydrochloride  97%

  • 1986-47-6

  • P22370-2.5G

  • 2,744.82CNY

  • Detail

1986-47-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name Tranylcypromine hydrochloride,(±)-trans-2-Phenylcyclopropylaminehydrochloride

1.2 Other means of identification

Product number -
Other names trans-2-Phenylcyclopropanamine hydrochloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1986-47-6 SDS

1986-47-6Synthetic route

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

Conditions
ConditionsYield
Stage #1: tranylcypromine hydrochloride With sodium hydrogencarbonate In water Inert atmosphere;
Stage #2: With L-Tartaric acid In methanol Sonication; Inert atmosphere; Further stages;
25%
(-)-(1R,2S)-trans (2-phenyl-cyclopropyl)carbaminic acid tert-butyl ester
185256-47-7

(-)-(1R,2S)-trans (2-phenyl-cyclopropyl)carbaminic acid tert-butyl ester

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

Conditions
ConditionsYield
With hydrogenchloride In tert-butyl alcohol at 100℃; for 0.333333h; Yield given;
With hydrogenchloride In tetrahydrofuran; water at 20℃; for 12h;
(+/-)-trans-2-phenylcyclopropanecarbonitrile

(+/-)-trans-2-phenylcyclopropanecarbonitrile

A

(+)-Tranylcypromine hydrochloride
4548-34-9

(+)-Tranylcypromine hydrochloride

B

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

Conditions
ConditionsYield
Multistep reaction. Title compound not separated from byproducts.;
trans-N-(2-phenylcyclopropyl)pivalamide

trans-N-(2-phenylcyclopropyl)pivalamide

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: hydrogenchloride; water / propan-1-ol / 40 h / 100 °C / Inert atmosphere
2.1: sodium hydrogencarbonate / water / Inert atmosphere
2.2: Sonication; Inert atmosphere
View Scheme
pivaloyl chloride
3282-30-2

pivaloyl chloride

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

N-((1R,2S)-2-phenylcyclopropyl)pivalamide

N-((1R,2S)-2-phenylcyclopropyl)pivalamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 1h; Inert atmosphere;97%
lauric acid
143-07-7

lauric acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

N-(2-phenylcyclopropyl)dodecanamide

N-(2-phenylcyclopropyl)dodecanamide

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;90%
(E)-methyl 3-(3-((4-oxopiperidin-1-yl)methyl)phenyl)acrylate

(E)-methyl 3-(3-((4-oxopiperidin-1-yl)methyl)phenyl)acrylate

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

(E)-methyl 3-(3-((4-(((trans)-2-phenylcyclopropyl)amino)piperidin-1-yl)methyl)phenyl)acrylate

(E)-methyl 3-(3-((4-(((trans)-2-phenylcyclopropyl)amino)piperidin-1-yl)methyl)phenyl)acrylate

Conditions
ConditionsYield
Stage #1: (E)-methyl 3-(3-((4-oxopiperidin-1-yl)methyl)phenyl)acrylate; tranylcypromine hydrochloride In 1,2-dichloro-ethane at 20℃; for 2h;
Stage #2: With sodium tris(acetoxy)borohydride In 1,2-dichloro-ethane at 0 - 20℃; for 4h;
89%
1-decanoic acid
334-48-5

1-decanoic acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

N-(2-phenylcyclopropyl)decanamide

N-(2-phenylcyclopropyl)decanamide

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;88%
2-({(3aR,4S,6R,6aS)-6-[7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-yl]-2,2-dimethyltetrahydro-3aH-cyclopentadiene[d][1,3]dioxolene-4-yl}oxy)ethanol

2-({(3aR,4S,6R,6aS)-6-[7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-yl]-2,2-dimethyltetrahydro-3aH-cyclopentadiene[d][1,3]dioxolene-4-yl}oxy)ethanol

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

2-(((3aR,4S,6R,6aS)-2,2-dimethyl-6-(7-(((1R,2S)-2-phenylcyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol

2-(((3aR,4S,6R,6aS)-2,2-dimethyl-6-(7-(((1R,2S)-2-phenylcyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol

Conditions
ConditionsYield
With triethylamine In acetonitrile at 80℃; for 2h;88%
(E)-methyl 3-(4-((4-oxopiperidin-1-yl)methyl)phenyl)acrylate

(E)-methyl 3-(4-((4-oxopiperidin-1-yl)methyl)phenyl)acrylate

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

C25H30N2O2

C25H30N2O2

Conditions
ConditionsYield
Stage #1: (E)-methyl 3-(4-((4-oxopiperidin-1-yl)methyl)phenyl)acrylate; tranylcypromine hydrochloride In 1,2-dichloro-ethane at 20℃; for 2h;
Stage #2: With sodium tris(acetoxy)borohydride In 1,2-dichloro-ethane at 0 - 20℃; for 14h;
82%
Octanoic acid
124-07-2

Octanoic acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

N-(2-phenylcyclopropyl)octanamide

N-(2-phenylcyclopropyl)octanamide

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;79%
hexanoic acid
142-62-1

hexanoic acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

N-(2-phenylcyclopropyl)hexanamide

N-(2-phenylcyclopropyl)hexanamide

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;78%
tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

butyric acid
107-92-6

butyric acid

N-(2-phenylcyclopropyl)butanamide

N-(2-phenylcyclopropyl)butanamide

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;78%
1-hexadecylcarboxylic acid
57-10-3

1-hexadecylcarboxylic acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

N-(2-phenylcyclopropyl)hexadecanamide

N-(2-phenylcyclopropyl)hexadecanamide

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;74%
methyl 4-((4-oxopiperidin-1-yl)methyl)benzoate
943767-91-7

methyl 4-((4-oxopiperidin-1-yl)methyl)benzoate

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

methyl 4-((4-(((trans)-2-phenylcyclopropyl)amino)piperidin-1-yl)methyl)benzoate

methyl 4-((4-(((trans)-2-phenylcyclopropyl)amino)piperidin-1-yl)methyl)benzoate

Conditions
ConditionsYield
Stage #1: methyl 4-[(4-oxopiperidin-1-yl)methyl]benzoate; tranylcypromine hydrochloride In 1,2-dichloro-ethane at 20℃; for 2h;
Stage #2: With sodium tris(acetoxy)borohydride In 1,2-dichloro-ethane at 0 - 20℃;
71%
n-tetradecanoic acid
544-63-8

n-tetradecanoic acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

N-(2-phenylcyclopropyl)tetradecanamide

N-(2-phenylcyclopropyl)tetradecanamide

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;70%
C17H15F2N3O3S

C17H15F2N3O3S

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

C26H26N4O4S

C26H26N4O4S

Conditions
ConditionsYield
In aq. phosphate buffer; acetonitrile at 37℃; pH=7.4;67%
2-thioxo-4-thiazolidinone
141-84-4

2-thioxo-4-thiazolidinone

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

2-((1R,2S)-2-phenyl-cyclopropylamino)-thiazol-4-one
872576-64-2

2-((1R,2S)-2-phenyl-cyclopropylamino)-thiazol-4-one

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; mercury dichloride In acetonitrile at 0 - 20℃; for 48h;42%
With N-ethyl-N,N-diisopropylamine; mercury dichloride In acetonitrile at 0 - 20℃; for 48h;42%
With N-ethyl-N,N-diisopropylamine; mercury dichloride In acetonitrile at 0 - 20℃; for 48.1667h;42%
3-(cyclopropylmethyl)-7-(iodomethyl)-8-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine
1374582-83-8

3-(cyclopropylmethyl)-7-(iodomethyl)-8-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

trans-N-{[3-(cyclopropylmethyl)-8-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridin-7-yl]methyl}-2-phenylcyclopropanamine

trans-N-{[3-(cyclopropylmethyl)-8-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridin-7-yl]methyl}-2-phenylcyclopropanamine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In acetonitrile at 90℃; for 18h; Sealed tube;21%
2(S)-(tert-Butoxycarbonylamino)hexanoic acid
125342-48-5

2(S)-(tert-Butoxycarbonylamino)hexanoic acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

[1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester

[1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;
Boc-Abu
34306-42-8

Boc-Abu

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

[(S)-1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-propyl]-carbamic acid tert-butyl ester

[(S)-1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-propyl]-carbamic acid tert-butyl ester

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;
2-tert-butoxycarbonylaminodecanoic acid
129938-57-4

2-tert-butoxycarbonylaminodecanoic acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

[1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-nonyl]-carbamic acid tert-butyl ester

[1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-nonyl]-carbamic acid tert-butyl ester

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;
2-(tert-butoxycarbonylamino)dodecanoic acid
129850-61-9

2-(tert-butoxycarbonylamino)dodecanoic acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

[1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-undecyl]-carbamic acid tert-butyl ester

[1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-undecyl]-carbamic acid tert-butyl ester

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;
2-(tert-butoxycarbonylamino)-D,L-tetradecanoic acid
129850-62-0

2-(tert-butoxycarbonylamino)-D,L-tetradecanoic acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

[1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-tridecyl]-carbamic acid tert-butyl ester

[1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-tridecyl]-carbamic acid tert-butyl ester

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;
2-((tert-butoxycarbonyl)amino)hexadecanoic acid
144315-64-0

2-((tert-butoxycarbonyl)amino)hexadecanoic acid

tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

[1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-pentadecyl]-carbamic acid tert-butyl ester

[1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-pentadecyl]-carbamic acid tert-butyl ester

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;
tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

N-tert-butoxycarbonyl-L-2-aminooctanoic acid
92211-95-5

N-tert-butoxycarbonyl-L-2-aminooctanoic acid

[(S)-1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-heptyl]-carbamic acid tert-butyl ester

[(S)-1-((1R,2S)-2-Phenyl-cyclopropylcarbamoyl)-heptyl]-carbamic acid tert-butyl ester

Conditions
ConditionsYield
With 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 24h;
tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

2-amino-N-(2-phenylcyclopropyl)butanamide

2-amino-N-(2-phenylcyclopropyl)butanamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-hydroxybenzotriazole hydrate; triethylamine; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride / CH2Cl2 / 24 h / 20 °C
2: trifluoroacetic acid / CH2Cl2 / 4 h / 20 °C
View Scheme
tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

N1-(2-phenylcyclopropyl)norleucineamide

N1-(2-phenylcyclopropyl)norleucineamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-hydroxybenzotriazole hydrate; triethylamine; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride / CH2Cl2 / 24 h / 20 °C
2: trifluoroacetic acid / CH2Cl2 / 4 h / 20 °C
View Scheme
tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

2-amino-N-(2-phenylcyclopropyl)octanamide

2-amino-N-(2-phenylcyclopropyl)octanamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-hydroxybenzotriazole hydrate; triethylamine; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride / CH2Cl2 / 24 h / 20 °C
2: trifluoroacetic acid / CH2Cl2 / 4 h / 20 °C
View Scheme
tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

2-amino-N-(2-phenylcyclopropyl)decanamide

2-amino-N-(2-phenylcyclopropyl)decanamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-hydroxybenzotriazole hydrate; triethylamine; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride / CH2Cl2 / 24 h / 20 °C
2: trifluoroacetic acid / CH2Cl2 / 4 h / 20 °C
View Scheme
tranylcypromine hydrochloride
1986-47-6

tranylcypromine hydrochloride

2-amino-N-(2-phenylcyclopropyl)dodecanamide

2-amino-N-(2-phenylcyclopropyl)dodecanamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-hydroxybenzotriazole hydrate; triethylamine; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride / CH2Cl2 / 24 h / 20 °C
2: trifluoroacetic acid / CH2Cl2 / 4 h / 20 °C
View Scheme

1986-47-6Relevant academic research and scientific papers

Diastereoselective Photoredox-Catalyzed [3 + 2] Cycloadditions of N-Sulfonyl Cyclopropylamines with Electron-Deficient Olefins

White, Dawn H.,Noble, Adam,Booker-Milburn, Kevin I.,Aggarwal, Varinder K.

supporting information, p. 3038 - 3042 (2021/05/04)

A highly diastereoselective, visible-light-induced [3 + 2] cycloaddition between N-sulfonyl cyclopropylamines and electron-deficient olefins is reported. The reactions proceed via the oxidation of a sulfonamide aza-anion by an organic photocatalyst to generate a nitrogen-centered radical. Strain-induced ring opening and intermolecular addition to the olefin generate an intermediate carbon-centered radical that is reduced to an anion prior to 5-exo cyclization. This enables a highly diastereoselective construction of trans-cyclopentanes possessing synthetically useful functional groups.

Cross-Coupling of Alkyl Redox-Active Esters with Benzophenone Imines: Tandem Photoredox and Copper Catalysis

Mao, Runze,Balon, Jonathan,Hu, Xile

, p. 9501 - 9504 (2018/07/29)

Alkyl amines are an important class of organic compounds in medicinal and materials chemistry. Until now very have been very few methods for the synthesis of alkyl amines by metal-catalyzed cross-coupling of alkyl electrophiles with nitrogen nucleophiles. Described here is an approach to employ tandem photoredox and copper catalysis to enable the cross-coupling of alkyl N-hydroxyphthalimide esters, readily derived from alkyl carboxylic acids, with benzophenone-derived imines. Hydrolysis of the coupling products furnish alkylated primary amines. Primary, secondary, and tertiary alkyl groups can be transferred, and the coupling tolerates a diverse set of functional groups. The method allows rapid functionalization of natural products and drugs, and can be used to expedite syntheses of pharmaceuticals from readily available chemical feedstocks.

C-H activation enables a rapid structure-activity relationship study of arylcyclopropyl amines for potent and selective LSD1 inhibitors

Miyamura, Shin,Araki, Misaho,Ota, Yosuke,Itoh, Yukihiro,Yasuda, Shusuke,Masuda, Mitsuharu,Taniguchi, Tomoyuki,Sowa, Yoshihiro,Sakai, Toshiyuki,Suzuki, Takayoshi,Itami, Kenichiro,Yamaguchi, Junichiro

supporting information, p. 8576 - 8585 (2016/09/28)

We describe the structure-activity relationship of various arylcyclopropylamines (ACPAs), which are potent LSD1 inhibitors. More than 45 ACPAs were synthesized rapidly by an unconventional method that we have recently developed, consisting of a C-H borylation and cross-coupling sequence starting from cyclopropylamine. We also generated NCD38 derivatives, which are known as LSD1 selective inhibitors, and discovered a more effective inhibitor compared to the original NCD38.

Stereodivergent synthesis of arylcyclopropylamines by sequential C-H borylation and Suzuki-Miyaura coupling

Miyamura, Shin,Araki, Misaho,Suzuki, Takayoshi,Yamaguchi, Junichiro,Itami, Kenichiro

supporting information, p. 846 - 851 (2015/02/19)

A step-economical and stereodivergent synthesis of privileged 2-arylcyclopropylamines (ACPAs) through a C-(sp3)-H borylation and Suzuki-Miyaura coupling sequence has been developed. The iridium-catalyzed C-H borylation of N-cyclopropylpivalamide proceeds with cis selectivity. The subsequent B-cyclopropyl Suzuki-Miyaura coupling catalyzed by [PdCl2(dppf)]/Ag2O proceeds with retention of configuration at the carbon center bearing the Bpin group, while epimerization at the nitrogen-bound carbon atoms of both the starting materials and products is observed under the reaction conditions. This epimerization is, however, suppressed in the presence of O2. The present new ACPA synthesis results in not only a significant reduction in the steps required for making ACPA derivatives, but also the ability to access either isomer (cis or trans) by simply changing the atmosphere (N2 or O2) in the coupling stage.

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

-

Page/Page column 141; 152; 153, (2013/05/09)

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2

Binda, Claudia,Valente, Sergio,Romanenghi, Mauro,Pilotto, Simona,Cirilli, Roberto,Karytinos, Aristotele,Ciossani, Giuseppe,Botrugno, Oronza A.,Forneris, Federico,Tardugno, Maria,Edmondson, Dale E.,Minucci, Saverio,Mattevi, Andrea,Mai, Antonello

supporting information; experimental part, p. 6827 - 6833 (2010/07/03)

LSD1 and LSD2 histone demethylases are implicated in a number of physiological and pathological processes, ranging from tumorigenesis to herpes virus infection. A comprehensive structural, biochemical, and cellular study is presented here to probe the potential of these enzymes for epigenetic therapies. This approach employs tranylcypromine as a chemical scaffold for the design of novel demethylase inhibitors. This drug is a clinically validated antidepressant known to target monoamine oxidases A and B. These two flavoenzymes are structurally related to LSD1 and LSD2. Mechanistic and crystallographic studies of tranylcypromine inhibition reveal a lack of selectivity and differing covalent modifications of the FAD cofactor depending on the enantiomeric form. These findings are pharmacologically relevant, since tranylcypromine is currently administered as a racemic mixture. A large set of tranylcypromine analogues were synthesized and screened for inhibitory activities. We found that the common evolutionary origin of LSD and MAO enzymes, despite their unrelated functions and substrate specificities, is reflected in related ligand-binding properties. A few compounds with partial enzyme selectivity were identified. The biological activity of one of these new inhibitors was evaluated with a cellular model of acute promyelocytic leukemia chosen since its pathogenesis includes aberrant activities of several chromatin modifiers. Marked effects on cell differentiation and an unprecedented synergistic activity with antileukemia drugs were observed. These data demonstrate that these LSD1/2 inhibitors are of potential relevance for the treatment of promyelocytic leukemia and, more generally, as tools to alter chromatin state with promise of a block of tumor progression.

Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors

Tsai, Ting-Yueh,Hsu, Tsu,Chen, Chiung-Tong,Cheng, Jai-Hong,Yeh, Teng-Kuang,Chen, Xin,Huang, Chung-Yu,Chang, Chung-Nien,Yeh, Kai-Chia,Hsieh, Su-Huei,Chien, Chia-Hui,Chang, Yi-Wei,Huang, Chih-Hsiang,Huang, Yu-Wen,Huang, Chen-Lung,Wu, Ssu-Hui,Wang, Min-Hsien,Lu, Cheng-Tai,Chao, Yu-Sheng,Jiaang, Weir-Torn

experimental part, p. 2388 - 2399 (2009/09/05)

A series of trans-2-aryl-cyclopropylamine derived compounds were synthesized and evaluated their biological activities against DPP-IV. The structure-activity relationships (SAR) led to the discovery of novel series of DPP-IV inhibitors, having IC50 values of 100 nM with excellent selectivity over the closely related enzymes, DPP8, DPP-II and FAP. The studies identified a potent and selective DPP-IV inhibitor 24b, which exhibited the ability to both significantly inhibit plasma DPP-IV activity in rats and improve glucose tolerance in lean mice and diet induced obese mice.

A novel approach to enantiopure cyclopropane compounds from biotransformation of nitriles

Wang, Mei-Xiang,Feng, Guo-Qiang

, p. 1575 - 1583 (2007/10/03)

Rhodococcus sp. AJ270, a powerful and versatile nitrile hydratase/amidase containing microbial whole-cell system, catalyzed the enantioselective hydrolysis of both racemic trans- and cis-2-arylcyclopropanecarbonitriles to afford the corresponding amides and acids with enantiomeric excesses as high as >99%. The reaction rate and enantioselectivity observed for both nitrile hydratase and amidase were also strongly dependent upon the nature of the substituent and substitution pattern on the benzene ring of the substrates. The application of and the advantages of biotransformation of nitriles were demonstrated by preparing (1S,2R)-2-phenylcyclopropylamine and (1R,2R)-2-phenylcyclopropylmethylamine through facile and straightforward chemical manipulations of (1S,2S)-2-phenylcyclopropanecarboxylic acid and (1R,2R)-2-phenylcyclopropanecarboxamide, respectively.

A catalytic enantioselective synthesis of antidepressant tranylcypromine

Shu, Fu-Chang,Zhou, Qi-Lin

, p. 567 - 572 (2007/10/03)

An efficient catalytic enantioselective synthesis of the antidepressant tranylcypromine is described.

trans-2-Aryl-N,N-dipropylcyclopropylamines: Synthesis and interactions with 5-HT(1A) receptors

Vallgarda,Appelberg,Arvidsson,Hjorth,Svensson,Hacksell

, p. 1485 - 1493 (2007/10/03)

Twelve N,N-dipropyl-substituted derivatives of trans-2- arylcyclopropylamine have been prepared and assayed for their ability to displace [3H]-8-OH-DPAT from rat brain 5-HT(1A) receptors. The new derivatives include phenyl (7a), bromo- (7b) and fluorophenyl (7c-e), 2- methoxy-5-fluorophenyl (7h), and 2-hydroxy-5-fluorophenyl (71) as well as trifluoromethylphenyl (7f) and 2,3-dichlorophenyl (7g) analogues. In the present series of compounds, electron-withdrawing substituents in the phenyl ring appear to decrease the affinity for 5-HT(1A) receptors. In contrast, electron-rich aryl groups, such as 2- or 3-thienyl (7j and 7k, respectively), provide compounds with high affinity. The additional bulk produced by the aromatic moiety in the 2-benzothienyl derivative 7i appears to be detrimental to 5-HT(1A) receptor affinity. The racemic mixtures of the interesting 7j and 7l were resolved into the enantiomers; 7j and 7l exhibited a high enantiomeric 5-HT(1A) receptor affinity ratio (75-fold and 100-fold, respectively). The enantiomers of 7j and 7l were evaluated in vivo by use of biochemical and behavioral tests in rats. Compound (1R,2R)-7j behaved as a partial agonist whereas (1R,2S)-7l appeared as an efficacious 5-HT(1A) receptor agonist, stimulating both autoreceptors and postsynaptic receptors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1986-47-6